The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
Global Blood Therapeutics Inc (GBT)

Global Blood Therapeutics is a biopharmaceutical company that engaged in the discovery, development and delivery of treatments to underserved patient communities. The U.S. Food and Drug Administration has granted approval for Co.'s Oxbryta® (voxelotor) tablets for the treatment of sickle cell disease (SCD) in adults and children 12 years of age and older. Oxbryta, an oral therapy taken once daily, is the treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD. Co. is developing treatments for SCD, including inclacumab, a P-selectin inhibitor used to reduce the incidence of vaso-occlusive crises and hemoglobin polymerization inhibitor, GBT021601, or GBT601.

Company Name:  Global Blood Therapeutics Inc
Website:  www.globalbloodtx.com
Sector:  Drugs & Pharmaceuticals
March 29, 2024    7:14 AM Eastern


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes

Email EnvelopeFree GBT Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Hold (2.47 out of 4)
58th percentile
(ranked higher than approx. 58% of all stocks covered)

Analysts' Target Price:
GBT Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Global Blood Therapeutics Inc (GBT) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.